ArticleTranslational oncology2026
Integrated single-cell and bulk transcriptomic analysis reveals an epithelial cell-derived prognostic and immunotherapeutic signature with ADAM12 as a key functional regulator in non-small cell lung cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study developed a Prognostic and Immunotherapeutic Signature (PIS) for NSCLC using single-cell and bulk RNA-seq data. By integrating TCGA and GEO datasets with machine learning, we identified key epithelial cells-related genes predictive of immunotherapy response. PIS effectively stratifies patients by survival and immune activity, with low-PIS individuals showing better outcomes and higher immune infiltration. We confirmed the high expression of ADAM12 in both tissue samples and cell lines, and validated its functional roles through cellular assays. Furthermore, mouse model experiments demonstrated that knockout ADAM12 enhances the efficacy of immunotherapy. In summary, these findings establish ADAM12 as a critical oncogenic driver and a candidate therapeutic target in NSCLC that warrants further validation, while also providing a robust tool for guiding personalized immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.